| Autor: | Mayhoub G, Aleem Sa, Rizk A, El-Aroussy W, Mokhtar Ms, El-Tobgy S |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Ejection fraction Ventricular function Heart disease Clinical chemistry business.industry Urinary system Clinical Biochemistry Dilated cardiomyopathy Cell Biology General Medicine medicine.disease Internal medicine Heart failure cardiovascular system medicine Cardiology cardiovascular diseases Carnitine business Molecular Biology medicine.drug |
| Zdroj: | Molecular and Cellular Biochemistry. 213:37-41 |
| ISSN: | 0300-8177 |
| Popis: | L-Carnitine plays a role in the utilization of fatty acids and glucose in the myocardium. Previous studies have indicated carnitine deficiency in patients with congestive heart failure. However, the extent of altered carnitine metabolism and left ventricular function is not fully determined. This study is designed to determine if plasma L-carnitine levels can serve as a marker for impaired left ventricular function in patients with congestive heart failure. To test this hypothesis, plasma and urinary levels of L-carnitine were measured in 30 patients with congestive heart failure (CHF) and in 10 control subjects. CHF was due to dilated cardiomyopathy (DCM) and rheumatic heart disease (RHD). Cardiac functions such as percentage of fractional shortening (%FS), ejection fraction (EF), left ventricular mass index (LVMI), were determined by echocardiography. All patients and control subjects had normal renal functions. Plasma carnitine was significantly higher in patients with DCM (37.05 ± 7.62, p 124 gm/m2 (r = 0.436, and p = 0.016). These data suggest that elevated plasma and urinary carnitine levels in patients with CHF could serve as a marker for myocardial damage and impaired left ventricular functions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink